Hard to Treat Diseases, Inc./ US41164A1034 /
30/05/2024 15:30:05 | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.0000USD | - | 13,000 Turnover: .0130 |
-Bid Size: - | -Ask Size: - | 0.0000 | 0.0000 |
GlobeNewswire
13/05
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conj...
GlobeNewswire
25/09/2023
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for ...
GlobeNewswire
08/10/2021
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2...
GlobeNewswire
30/06/2021
Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) fr...
GlobeNewswire
20/05/2021
Predictive Oncology Inc.’s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate AB
GlobeNewswire
28/10/2019
PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology...
GlobeNewswire
15/10/2019
WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Mar...
GlobeNewswire
25/09/2019
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Te...
Newsfile Corp
17/09/2019
cbdMD Sales Growing, Key Influencers Continue to Bring the Product Mainstream-- CFN Media
GlobeNewswire
29/07/2019
Innovation Pharmaceuticals Provides Corporate Update Highlighting Clinical Pipeline Progress and Bus...
GlobeNewswire
02/11/2018
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology